The Fight Against COVID19
23.12k followers • 14 symbols Watchlist by TREA
Follow this list to discover and track the stock of publicly traded companies with COVID-19 related treatment and healthcare plans.
Curated by TREA
Performance
| Watchlist | Change Today | 1 Month Return | 1 Year Return | Total Return |
|---|---|---|---|---|
| The Fight Against COVID19 | -3.37% | - | - | - |
| ^GSPC | -1.89% | -8.21% | +14.07% | +4628.97% |
14 Symbols
| Symbol | Company Name | Last Price | Change | % Change | Market Time | Volume | Avg Vol (3 month) | Market Cap |
|---|---|---|---|---|---|---|---|---|
| JNJ | Johnson & Johnson | 164.87 | -0.38 | -0.23% | 4:00 p.m. EST | 10.55M | 7.55M | 434.04B |
| PFE | Pfizer Inc. | 52.79 | -1.26 | -2.33% | 4:02 p.m. EST | 41.06M | 44.01M | 296.30B |
| ABBV | AbbVie Inc. | 131.98 | -1.05 | -0.79% | 4:02 p.m. EST | 7.58M | 6.57M | 233.32B |
| SNY | Sanofi | 51.24 | -0.85 | -1.63% | 4:00 p.m. EST | 1.56M | 1.56M | 128.79B |
| GSK | GlaxoSmithKline plc | 45.1 | +0.22 | +0.49% | 4:00 p.m. EST | 5.47M | 4.23M | 113.47B |
| GILD | Gilead Sciences, Inc. | 68.51 | +0.70 | +1.03% | 4:00 p.m. EST | 14.84M | 7.47M | 85.94B |
| REGN | Regeneron Pharmaceuticals, Inc. | 621.4 | +7.02 | +1.14% | 4:00 p.m. EST | 1.33M | 758.76k | 66.83B |
| MRNA | Moderna, Inc. | 160.07 | -7.45 | -4.45% | 4:00 p.m. EST | 11.80M | 11.89M | 64.90B |
| TAK | Takeda Pharmaceutical Company Limited | 14.66 | +0.26 | +1.81% | 4:00 p.m. EST | 7.85M | 2.74M | 45.67B |
| BNTX | BioNTech SE | 147.5 | -9.03 | -5.77% | 4:00 p.m. EST | 4.40M | 3.43M | 35.77B |
| NVAX | Novavax, Inc. | 84.65 | -5.71 | -6.32% | 4:00 p.m. EST | 5.76M | 5.99M | 6.40B |
| VIR | Vir Biotechnology, Inc. | 33.46 | +0.32 | +0.97% | 4:00 p.m. EST | 1.33M | 1.72M | 4.38B |
| INO | Inovio Pharmaceuticals, Inc. | 3.92 | -0.18 | -4.39% | 4:00 p.m. EST | 6.32M | 4.54M | 824.71M |
- Bloomberg
Unilever CEO’s Woes Grow With Arrival of Activist Investor Peltz
(Bloomberg) -- A stake that Nelson Peltz’s activist hedge fund has built in Unilever Plc is adding to pressure on the Dove soap maker’s chief executive officer, Alan Jope, after Jope’s failed bid to buy a consumer-health unit from GlaxoSmithKline Plc.Most Read from BloombergCrypto Crash Erases More Than $1 Trillion in Market ValueU.S. Stocks Historically Deliver Strong Gains in Fed Hike CyclesMorgan Stanley’s Slimmon Warns Against Buying Growth-Stock DipPutin Could Burst Xi’s Olympic Dream With
- The Telegraph
Activist stake piles more pressure on Unilever boss
Unilever's management risks coming under further pressure after an aggressive activist investor was reported to have built a stake in the Marmite maker.
- Motley Fool
Why Pfizer's Deal With Beam Therapeutics Is a Smart Move
Pfizer (NYSE: PFE) recently announced a collaboration with Beam Therapeutics (NASDAQ: BEAM) to develop gene-editing therapies targeting rare genetic diseases. In this Motley Fool Live video, recorded on Jan. 12., Fool contributors Keith Speights and Brian Orelli discuss why Pfizer's deal with Beam appears to be a smart move. Keith Speights: We mentioned this on Monday I believe, that Pfizer had announced a collaboration with Beam Therapeutics to develop therapies targeting rare genetic diseases.
